Evolution of Pulse Pressure Following Initiation of Antihypertensive Therapy in Patients With Essential Arterial Hypertension

Completed

• Conditions: Hypertension
• Interventions: Drug: Micardis®; Drug: Other hypertensives

• Registration Number: NCT02202525
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

The main purpose of this prospective, multicentre, french observational study is to analyse the evolution of pulse pressure (PP) and to identify its prognostic factors in hypertensive patients three months after initiation of a new hypertensive therapy. The PP is defined as the difference between systolic blood pressure (SBP) and diastolic blood pressure (DBP).

Detailed Description

Not available

Study Timeline

• Study Start: 2001-01
• Primary Completion: 2002-03
• Status Verified: 2014-07
• Study First Submitted: 2014-07-28
• Study First Submitted QC: 2014-07-28
• Last Update Submitted: 2014-07-28
• Study First Posted: 2014-07-29
• Last Update Posted: 2014-07-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2148

Inclusion Criteria

• Patients with essential arterial hypertension needing a new antihypertensive therapy
• A patient was included by the physician only if he/she had agreed after being informed about the study

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Essential arterial hypertension	Other hypertensives	Patients with essential arterial hypertension needing a new antihypertensive therapy
Essential arterial hypertension	Micardis®	Patients with essential arterial hypertension needing a new antihypertensive therapy

Primary Outcome Measures

Name	Time	Method
Changes from baseline in pulse pressure	Up to 3 months after start of treatment
Number of patients with adverse drug reactions	Up to 3 months after start of treatment